“Valuations and earnings matter” in this “Goldilocks scenario,” says Lara Castleton. “There’s two things that have worked this year…international equities, and healthcare.” She notes that these have been under-appreciated for a while, and thinks investors should stock-pick within these sectors. However, she says picking within biotech is “extremely difficult.”